The National Institutes of Health Cap on Indirect Rates for Research Institutions-Law and Policy

Lawrence O Gostin; Jennifer S Bard

doi:10.1001/jama.2025.6238

The National Institutes of Health Cap on Indirect Rates for Research Institutions-Law and Policy

JAMA. 2025 Jun 3;333(21):1857-1858. doi: 10.1001/jama.2025.6238.

Authors

Lawrence O Gostin¹, Jennifer S Bard^{2

3}

Affiliations

¹ O'Neill Institute for National and Global Health Law, Georgetown University, Washington, DC.
² University of Cincinnati School of Law, Cincinnati, Ohio.
³ Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.

PMID: 40238587
DOI: 10.1001/jama.2025.6238

No abstract available

Plain language summary

This Viewpoint examines the National Institutes of Health’s 15% uniform cap on indirect cost reimbursements for all federally funded biomedical research and the litigation that followed from a coalition of 22 states.

Publication types

Comment